Future directions in the pharmacology of anti-cancer agents in children.
In the 1990s, over two-thirds of children with malignancy are expected to be long term survivors. This success in therapy is predominantly due to the chemosensitivity of childhood tumours as well as co-ordinated multi-disciplinary care through the use of protocols and designated children's cancer centres. In view of the pivotal importance of chemotherapy in childhood malignancies in the future therapy can be improved considerably by exploring ways to optimise treatment either by introducing new agents or utilising existing drugs better.
Pearson
A D
AD
Sir James Spence Institute of Child Health, University of Newcastle upon Tyne, UK.
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005544:Forecasting; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents